Medicare U-Turn Sends Health Insurers Soaring After Hours

The Wall Street Journal, Axios, Bloomberg, and Market Watch contributed to this report.

Wall Street didn’t wait long to react. A late-day policy shift out of Washington sent health insurance stocks sharply higher, with some names jumping double digits in after-hours trading.

The trigger: the Trump administration’s decision to boost payments to Medicare Advantage insurers by 2.48% in 2027 – far more generous than its earlier plan to keep rates basically flat.

Investors piled in.

UnitedHealth Group climbed 8.5%, a big move for a heavyweight in the Dow. Humana surged even more, up 11%. Elevance Health added 7.4%, while Molina Healthcare and Centene posted solid gains as well. Even CVS Health – part pharmacy chain, part insurance player – jumped 8%.

That’s a broad rally across the sector, and it didn’t come out of nowhere.

Just a few months ago, insurers were staring at a near-freeze in federal payments. The initial proposal in January barely nudged rates higher, sparking a selloff in Medicare-focused stocks. The final decision flips that script. Not only is the 2.48% increase at the upper end of expectations, but when adjusted for patient health data, the effective bump could approach 5%.

That’s real money – about $13 billion more flowing into the system.

The change reflects a simple reality: healthcare costs are rising faster than expected. New data from late 2025 showed traditional Medicare getting more expensive, forcing policymakers to rethink their earlier stance.

Regulators also backed off a controversial proposal to tweak how insurers are paid based on patient risk profiles. The industry had pushed back hard, arguing the changes would disrupt care for seniors. For now, they’ve bought some time.

Still, this isn’t a full victory lap.

Officials are moving ahead with a crackdown on certain billing practices – specifically, how insurers add diagnoses after reviewing medical records. That move alone is expected to save nearly $7 billion next year. In other words, more money in one hand, tighter rules in the other.

There’s also a bigger tension that hasn’t gone away. Washington has long worried that Medicare Advantage plans cost too much. That concern cuts across party lines, and it’s not disappearing just because payments are going up.

Industry groups say the increase still may not be enough. Medical inflation is biting – drug prices, staffing, more frequent patient visits. If reimbursements lag too far behind, insurers could start trimming benefits or pulling out of less profitable markets. That’s already happening in some states.

Behind the scenes, regulators are trying to walk a fine line: keep insurers in the game while avoiding a blowout in federal spending.

The timing matters, too. With elections on the horizon, Medicare is never just a policy issue. It’s political fuel. Insurers have run aggressive ad campaigns in the past when payment changes didn’t go their way. Whether they’ll do it again depends on how this new rate plays out in practice.

For now, though, the market has made up its mind.

The government blinked. Insurers get a bigger slice. And investors, at least for one evening, liked what they saw.